Esperion Therapeutics Stock Market Outlook
| ESPR Stock | USD 3.43 0.03 0.88% |
Slightly above 63% of all Esperion Therapeutics' retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding Esperion Therapeutics suggests that some traders are interested. Esperion Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Esperion Therapeutics. Many technical investors use Esperion Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 63
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Esperion Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Esperion Therapeutics.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Esperion Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Esperion Therapeutics within the specified time frame.
Execute Esperion Therapeutics Advice
The Esperion recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Esperion Therapeutics. Macroaxis does not own or have any residual interests in Esperion Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Esperion Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Fair | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
For the selected time horizon Esperion Therapeutics has a Mean Deviation of 3.34, Semi Deviation of 3.58, Standard Deviation of 4.29, Variance of 18.42, Downside Variance of 15.46 and Semi Variance of 12.83We provide trade advice to complement the prevailing expert consensus on Esperion Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Esperion Therapeutics is not overpriced, please confirm all Esperion Therapeutics fundamentals, including its total debt, and the relationship between the revenue and price to earnings to growth . Given that Esperion Therapeutics has a number of shares shorted of 33.45 M, we urge you to verify Esperion Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Esperion Therapeutics Trading Alerts and Improvement Suggestions
| Esperion Therapeutics had very high historical volatility over the last 90 days | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 131.9 M. | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79. | |
| Esperion Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Esperion Therapeutics Stock Rating Upgraded by Wall Street Zen |
Esperion Therapeutics Returns Distribution Density
The distribution of Esperion Therapeutics' historical returns is an attempt to chart the uncertainty of Esperion Therapeutics' future price movements. The chart of the probability distribution of Esperion Therapeutics daily returns describes the distribution of returns around its average expected value. We use Esperion Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Esperion Therapeutics returns is essential to provide solid investment analysis for Esperion Therapeutics.
| Mean Return | 0.35 | Value At Risk | -7.02 | Potential Upside | 6.92 | Standard Deviation | 4.29 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Esperion Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Esperion Stock Institutional Investors
The Esperion Therapeutics' institutional investors refer to entities that pool money to purchase Esperion Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Two Sigma Investments Llc | 2025-06-30 | 1.8 M | Northern Trust Corp | 2025-06-30 | 1.8 M | Ubs Group Ag | 2025-06-30 | 1.5 M | Woodline Partners Lp | 2025-06-30 | 1.5 M | Royal Bank Of Canada | 2025-06-30 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.1 M | Susquehanna International Group, Llp | 2025-06-30 | 836.5 K | Bank Of America Corp | 2025-06-30 | 836.3 K | Goldman Sachs Group Inc | 2025-06-30 | 798.8 K | Blackrock Inc | 2025-06-30 | 14.7 M | Vanguard Group Inc | 2025-06-30 | 11.7 M |
Esperion Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change To Inventory | (18.3M) | (807K) | (30.4M) | (28.9M) | (26.0M) | (24.7M) | |
| Change In Cash | (46.1M) | (134.1M) | (42.5M) | 62.5M | 56.3M | 59.1M | |
| Free Cash Flow | (263.8M) | (174.8M) | (135.5M) | (24.0M) | (21.6M) | (22.7M) | |
| Depreciation | 612K | 500K | 164K | 63K | 72.5K | 76.1K | |
| Other Non Cash Items | 32.9M | 46.5M | 48.0M | 76.6M | 88.0M | 92.5M | |
| Capital Expenditures | 953K | 13.4M | 0.0 | 317K | 364.6K | 346.3K | |
| Net Income | (269.1M) | (233.7M) | (209.2M) | (51.7M) | (46.6M) | (48.9M) | |
| End Period Cash Flow | 258.9M | 124.8M | 82.2M | 144.8M | 166.5M | 98.2M | |
| Investments | (50.5M) | 8.1M | 30.7M | (317K) | (364.6K) | (382.8K) | |
| Change To Netincome | 25.9M | 28.4M | 21.7M | 15.2M | 17.5M | 18.7M | |
| Net Borrowings | 225.6M | (440K) | 0.0 | 35.0M | 40.3M | 54.0M |
Esperion Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Esperion Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Esperion Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Esperion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.17 | |
β | Beta against Dow Jones | 2.95 | |
σ | Overall volatility | 4.27 | |
Ir | Information ratio | 0.07 |
Esperion Therapeutics Volatility Alert
Esperion Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Esperion Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Esperion Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Esperion Therapeutics Fundamentals Vs Peers
Comparing Esperion Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Esperion Therapeutics' direct or indirect competition across all of the common fundamentals between Esperion Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Esperion Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Esperion Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Esperion Therapeutics to competition |
| Fundamentals | Esperion Therapeutics | Peer Average |
| Return On Equity | -2.61 | -0.31 |
| Return On Asset | -0.0542 | -0.14 |
| Profit Margin | (0.35) % | (1.27) % |
| Operating Margin | (0.11) % | (5.51) % |
| Current Valuation | 1.03 B | 16.62 B |
| Shares Outstanding | 239.06 M | 571.82 M |
| Shares Owned By Insiders | 0.61 % | 10.09 % |
| Shares Owned By Institutions | 53.55 % | 39.21 % |
| Number Of Shares Shorted | 33.45 M | 4.71 M |
| Price To Earning | (8.19) X | 28.72 X |
| Price To Book | 98.42 X | 9.51 X |
| Price To Sales | 2.70 X | 11.42 X |
| Revenue | 332.31 M | 9.43 B |
| Gross Profit | 131.9 M | 27.38 B |
| EBITDA | 7.57 M | 3.9 B |
| Net Income | (51.74 M) | 570.98 M |
| Cash And Equivalents | 185.84 M | 2.7 B |
| Cash Per Share | 2.79 X | 5.01 X |
| Total Debt | 591.21 M | 5.32 B |
| Current Ratio | 3.07 X | 2.16 X |
| Book Value Per Share | (2.20) X | 1.93 K |
| Cash Flow From Operations | (23.65 M) | 971.22 M |
| Short Ratio | 5.99 X | 4.00 X |
| Earnings Per Share | (0.54) X | 3.12 X |
| Price To Earnings To Growth | (4.78) X | 4.89 X |
| Target Price | 6.51 | |
| Number Of Employees | 304 | 18.84 K |
| Beta | 1.11 | -0.15 |
| Market Capitalization | 819.99 M | 19.03 B |
| Total Asset | 343.82 M | 29.47 B |
| Retained Earnings | (1.6 B) | 9.33 B |
| Working Capital | 91.77 M | 1.48 B |
| Current Asset | 214.39 M | 9.34 B |
Note: Disposition of 1689 shares by Benjamin Looker of Esperion Therapeutics at 2.882 subject to Rule 16b-3 [view details]
Esperion Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Esperion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Esperion Therapeutics Target Price Consensus
Esperion target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Esperion Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Buy |
Most Esperion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Esperion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Esperion Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEsperion Therapeutics Target Price Projection
Esperion Therapeutics' current and average target prices are 3.43 and 6.51, respectively. The current price of Esperion Therapeutics is the price at which Esperion Therapeutics is currently trading. On the other hand, Esperion Therapeutics' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Esperion Therapeutics Market Quote on 15th of February 2026
Target Price
Analyst Consensus On Esperion Therapeutics Target Price
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Esperion Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Esperion Therapeutics' financials, market performance, and future outlook by experienced professionals. Esperion Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Esperion Therapeutics Buy or Sell Advice
When is the right time to buy or sell Esperion Therapeutics? Buying financial instruments such as Esperion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Esperion Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.